The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Frontiers in Molecular Biosciences, Год журнала: 2022, Номер 9

Опубликована: Дек. 2, 2022

Background: The albumin levels may potentially be used as a prognostic biomarker in patients with cancertreated immune checkpoint inhibitors (ICIs) due to its close relationship nutritional and inflammatory status. However, the available data is limited heterogeneous patient cohorts, sample sizes variable cut-offs. Therefore, we conducted systematic review meta-analysis evaluate association between survival outcomes treated ICIs. Methods: We using PubMed, Web of Science, Embase databases filter published studies up 1 June 2022. meta-analyses were performed generic inverse-variance method random-effects model high degree heterogeneity. primary outcome measure was hazard ratio (HR) 95% confidence intervals (CI). study protocol registered PROSPERO registry (Registration Number: CRD42022337746). Results: Thirty-six encompassing 8406 cancer advanced disease included meta-analyses. Almost half NSCLC cohorts (n = 15), 3.5 gr/dL most frequently cut-off 20). Patients lower had significantly increased risk death (HR: 1.65, CI: 1.52–1.80, p < 0.0001) than higher levels. Subgroup analyses for location, size, tumor type demonstrated consistent results. Furthermore, subgroup analysis eight continuous factor, every decrease associated by factor 10% 1.10, 1.05–1.16, 0.0002). Similar overall survival, an progression or compared 1.76, 1.40–2.21, 0.001). Conclusion: evidence demonstrates that Further research needed delineate role ICIs adjuvant setting, well possible benefit therapeutic approaches improve hypoalbuminemia.

Язык: Английский

---

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Journal of Hematology & Oncology, Год журнала: 2022, Номер 15(1)

Опубликована: Авг. 28, 2022

Immune checkpoint inhibitors targeting programmed cell death protein 1, death-ligand and cytotoxic T-lymphocyte-associated 4 provide deep durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% gain benefit. A key understanding what differentiates response from non-response is better defining the role innate immune system in anti-tumor immunity tolerance. Teleologically, myeloid cells, including macrophages, dendritic monocytes, neutrophils, initiate a invading pathogens tissue repair after pathogen clearance successfully accomplished. tumor microenvironment (TME), these cells are hijacked by imprinted furthering propagation dissemination. Major advancements been made field, especially related heterogeneity their function TME at single level, topic that has highlighted several recent international meetings 2021 China Cancer Immunotherapy workshop Beijing. Here, we an up-to-date summary mechanisms major facilitate immunosuppression, enable growth, foster plasticity, confer therapeutic resistance. We discuss ongoing strategies compartment preclinical clinical settings include: (1) altering composition within TME; (2) functional blockade immune-suppressive cells; (3) reprogramming acquire pro-inflammatory properties; (4) modulating via cytokines; (5) therapies; (6) emerging targets such as Siglec-15, TREM2, MARCO, LILRB2, CLEVER-1. There significant promise cell-based immunotherapy will help advance immuno-oncology years come.

Язык: Английский

---

Recent Advances and Challenges in Cancer Immunotherapy

Cancers, Год журнала: 2022, Номер 14(16), С. 3972 - 3972

Опубликована: Авг. 17, 2022

Cancer immunotherapy has revolutionized the field of oncology in recent years. Harnessing immune system to treat cancer led a large growth number novel immunotherapeutic strategies, including checkpoint inhibition, chimeric antigen receptor T-cell therapy and vaccination. In this review, we will discuss current landscape immuno-oncology research, with focus on elements that influence outcomes. We also highlight advances basic aspects tumor immunology, particular, role immunosuppressive cells within microenvironment regulating antitumor immunity. Lastly, how understanding immunology can lead development new strategies.

Язык: Английский

---

Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment

Journal of Clinical Medicine, Год журнала: 2023, Номер 12(13), С. 4301 - 4301

Опубликована: Июнь 27, 2023

Checkpoint proteins are an integral part of the immune system and used by tumor cells to evade response, which helps them grow uncontrollably. By blocking these proteins, checkpoint inhibitors can restore capability attack cancer stop their growth. These findings backed adequate clinical trial data presently, several FDA-approved exist in market for treating various types cancers, including melanoma, hepatocellular, endometrial, lung, kidney others. Their mode action is inhibition targeting CTLA-4, PD-1, PD-L1, etc. They be alone as well amalgamation with other treatments, like surgery, radiation or chemotherapy. Since drugs target only specific side effects reduced comparison traditional chemotherapy drugs, but may still cause a few affects fatigue, skin rashes, fever. In rare cases, known have caused more serious effects, such cardiotoxicity, inflammation intestines lungs. Herein, we provide overview role biomarkers, immune-related adverse outcomes studies treatment present some future perspectives.

Язык: Английский

---

The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress

Bioconjugate Chemistry, Год журнала: 2023, Номер 34(11), С. 1951 - 2000

Опубликована: Окт. 11, 2023

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate the potency of cytotoxic drugs with selectivity monoclonal antibodies, minimizing damage to healthy cells and reducing systemic toxicity. Their design allows for higher doses drug be administered, potentially increasing efficacy. They currently among most promising classes in oncology, efforts expand their application nononcological indications combination therapies. Here we provide a detailed overview recent advances ADC research consider future directions challenges promoting this platform widespread therapeutic use. We examine data from CAS Content Collection, largest human-curated collection published scientific information, analyze publication landscape reveal exploration trends documents insights into area. also discuss evolution key concepts field, major technologies, development pipelines company focuses, disease targets, stages, investment trends. A comprehensive concept map has been created based on Collection. hope report can serve as useful resource understanding current state knowledge field ADCs remaining fulfill potential.

Язык: Английский

---

Immune checkpoint inhibitor combinations—current and emerging strategies

British Journal of Cancer, Год журнала: 2023, Номер 128(8), С. 1415 - 1417

Опубликована: Фев. 6, 2023

Язык: Английский

---

Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells

Cancers, Год журнала: 2024, Номер 16(13), С. 2478 - 2478

Опубликована: Июль 7, 2024

The rise of drug resistance in cancer cells presents a formidable challenge modern oncology, necessitating the exploration innovative therapeutic strategies. This review investigates latest advancements overcoming mechanisms employed by cells, focusing on emerging modalities. intricate molecular insights into resistance, including genetic mutations, efflux pumps, altered signaling pathways, and microenvironmental influences, are discussed. Furthermore, promising avenues offered targeted therapies, combination treatments, immunotherapies, precision medicine approaches highlighted. Specifically, synergistic effects combining traditional cytotoxic agents with molecularly inhibitors to circumvent pathways examined. Additionally, evolving landscape immunotherapeutic interventions, immune checkpoint adoptive cell is explored terms bolstering anti-tumor responses evasion mechanisms. Moreover, significance biomarker-driven strategies for predicting monitoring treatment underscored, thereby optimizing outcomes. For future direction paradigms, current focused prevailing challenges improving patient outcomes, through an integrative analysis these

Язык: Английский

---

Network-based drug repurposing identifies small molecule drugs as immune checkpoint inhibitors for endometrial cancer

Molecular Diversity, Год журнала: 2024, Номер unknown

Опубликована: Янв. 16, 2024

Язык: Английский

---

CD73/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies

Frontiers in Cell and Developmental Biology, Год журнала: 2025, Номер 12

Опубликована: Янв. 13, 2025

Consolidation with PD-1/PD-L1-based immune checkpoint blockade after concurrent platinum-based chemo-radiotherapy has become the new standard of care for advanced stage III unresectable non-small cell lung cancer (NSCLC) patients. In order to further improve therapy outcomes, innovative combinatorial treatment strategies aim target additional immunosuppressive barriers in tumor microenvironment such as CD73/adenosine pathway. CD73 and adenosine are known crucial endogenous regulators homeostasis inflammation, but also contribute an microenvironment. Furthermore, pathway can limit immune-activating effects cytotoxic therapies by degrading pro-inflammatory danger molecule ATP, which is released into normal tissue upon therapy-induced damage. Thus, while targeting may enhance efficacy radio-immunotherapies mitigating escape improving immune-mediated killing, it raises concerns about increased immune-related adverse events (irAEs) tissue. fact, combined bear risk irAEs lungs, pharmacologic inhibition overwhelming or overlapping pulmonary toxicity thereby outcome. This review explores how therapeutic interventions dynamics could radiation-induced activation radio-immunotherapies, whilst potentially driving lung. We specifically investigate interactions between radiotherapy radiation pneumonitis. Additionally, we compare incidence (radiation) pneumonitis reported relevant trials determine if there clinical setting. By understanding these dynamics, inform future optimizing radio-immunotherapy regimens, ensuring effective control preserving integrity patient quality life.

Язык: Английский

---

Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(3), С. 2858 - 2858

Опубликована: Фев. 2, 2023

Macrophages are versatile immune cells and can adapt to both external stimuli their surrounding environment. categorized into two major categories; M1 macrophages release pro-inflammatory cytokines produce protective responses that lead antimicrobial or antitumor activity. M2 tumor-associated (TAM) anti-inflammatory support tumor growth, invasion capacity, metastatic potential. Since be re-polarized from an phenotype with a variety of strategies, this has emerged as innovative anti-cancer approach. Osteosarcoma (OS) is kind bone cancer consists complex niche, immunotherapy not very effective. Therefore, immediate attention new strategies required. We incorporated the recent studies have used M2-M1 repolarization in aspect treating OS cancer.

Язык: Английский

---